SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
何静cpu
Lv4
480 积分
2022-02-14 加入
最近求助
最近应助
互助留言
Discovery of Potent, Dual-Inhibitors of Diacylglycerol Kinases Alpha and Zeta Guided by Phenotypic Optimization
13天前
已完结
The diacylglycerol kinase ζ inhibitor ASP1570 augments natural killer cell function
13天前
已完结
PD1/PDL1 clinical trials adapt to a growing landscape of patients resistant to PDx
6个月前
已完结
Bystander T cells in cancer immunology and therapy
7个月前
已完结
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
8个月前
已完结
Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)
8个月前
已关闭
Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)
8个月前
已关闭
Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)
8个月前
已关闭
The Wild West of Checkpoint Inhibitor Development
8个月前
已完结
Global consequences of the US FDA's accelerated approval of cancer drugs
1年前
已完结
没有进行任何应助
帮大忙了
6个月前
非常感谢可爱的你!
6个月前
速度真快,感谢
7个月前
不需要了【积分已退回】
8个月前
感谢,速度真快
8个月前
速度真快
1年前
感谢,速度真快
2年前
感谢
2年前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论